Our research focuses on the molecular and cellular physiopathology of blood cancers, particularly on acute myeloid leukemia (LMA) and chronic lymphatic leukemia (CLL) where we seek to find new treatment options targeting molecular features. Also, we study the prognostic value of clinical and biological features in malignant hemopathies, like LMA and CLL.
We study the transplant of hematopoietic progenitors and its complications and develop new academic CAR-T cells enriched in T-memory stem cells to treat T and B Hodgkin lymphomas.
It is paramount that we improve the prognosis of hematological patients by using new more precise therapies, and less toxic. Therefore, through our research, we aim to:
Improve the genotypic and immunophenotypic characterization of AML and CLL, to identify new prognostic factors and administer targeted therapy.
Improve the safety and effectiveness of hematopoietic transplantation and expand the number of patients who can benefit from it.
Develop new CAR-T products that enhance the currently commercially available ones.